{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:55:58Z","timestamp":1761872158729,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["10\/50344-0"],"award-info":[{"award-number":["10\/50344-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clml.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T12:21:13Z","timestamp":1678364473000},"page":"438-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of KIR Genes Polymorphism and its HLA Ligands in Diffuse Large B-cell Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-8482","authenticated-orcid":false,"given":"Cardozo","family":"Daniela Maira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marangon","family":"Amanda Vansan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-972X","authenticated-orcid":false,"given":"Guimar\u00e3es","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marques","family":"Silvia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieber","family":"Sofia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delamain","family":"M\u00e1rcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aranha","family":"Francisco Jos\u00e9 Penteado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Visentainer","family":"Jeane Eliete Laguila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"de Souza","family":"C\u00e1rmino Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2023.03.001_bib0001","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3109\/10428194.2015.1014361","article-title":"Natural killer cell killer immunoglobulin-like gene receptor polymorphisms in non-Hodgkin lymphoma: possible association with clinical course","volume":"56","author":"Pamuk","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2023.03.001_bib0002","first-page":"5","article-title":"Epidemiology of non-hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2023.03.001_bib0003","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"issue":"6769","key":"10.1016\/j.clml.2023.03.001_bib0004","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.clml.2023.03.001_bib0005","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2023.03.001_bib0006","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-oforigin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin's lymphoma study group","volume":"22","author":"Staiger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.03.001_bib0007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.001_bib0008","unstructured":"FERREIRA, Juliana Moreira de Oliveira. Incid\u00eancia, mortalidade e sobrevida de leucemia e linfoma no Munic\u00edpio de Fortaleza, Cear\u00e1. 2010. 106 f. Disserta\u00e7\u00e3o (Mestrado em Sa\u00fade P\u00fablica e meio Ambiente) - Escola Nacional de Sa\u00fade, Funda\u00e7\u00e3o Oswaldo Cruz, Rio de Janeiro, 2010."},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.03.001_bib0009","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.clml.2011.03.029","article-title":"Non-Hodgkin's lymphoma: the old and the new","volume":"11","author":"Cabanillas","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.001_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.03.001_bib0011","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.001_bib0012","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.12459","article-title":"Weekly rituximab consolidation following four cycles of RCHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: consortium for improving survival of lymphoma study (CISL)","volume":"94","author":"Jung","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.03.001_bib0013","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large Bcell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.001_bib0014","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.001_bib0015","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.03.001_bib0016","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","article-title":"Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.03.001_bib0017","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.2425","article-title":"Nonpegylated liposomal doxorubicin combination Curr Hematol Malig Rep (2019) 14:207\u2013218 217 regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi","volume":"36","author":"Luminari","year":"2018","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.03.001_bib0018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-019-00518-8","article-title":"Front-line treatment of high grade B cell Non-Hodgkin Lymphoma","volume":"14","author":"Kesavan","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.clml.2023.03.001_sbref0019","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5858\/2008-132-118-DLBL","article-title":"Diffuse large B-cell lymphoma","volume":"132","author":"Hunt","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"19","key":"10.1016\/j.clml.2023.03.001_bib0020","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1182\/blood-2009-10-250134","article-title":"Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma","volume":"115","author":"Stern","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2023.03.001_bib0021","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clml.2023.03.001_bib0022","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.genom.7.080505.115726","article-title":"The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense","volume":"7","author":"Bashirova","year":"2006","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.clml.2023.03.001_bib0023","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-065X.2006.00459.x","article-title":"KIR and disease: a model system or system of models?","volume":"214","author":"Khakoo","year":"2006","journal-title":"Immunol Rev"},{"issue":"13","key":"10.1016\/j.clml.2023.03.001_bib0024","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2008-06-164103","article-title":"Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity","volume":"113","author":"Pende","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.03.001_bib0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.humimm.2014.04.004","article-title":"Killer cell immunoglobulin-like receptors in Thai patients with leukemia and diffuse large B-cell lymphoma","volume":"75","author":"Vejbaesya","year":"2014","journal-title":"Hum Immunol"},{"issue":"Database issue","key":"10.1016\/j.clml.2023.03.001_bib0026","doi-asserted-by":"crossref","first-page":"D913","DOI":"10.1093\/nar\/gkq1128","article-title":"Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations","volume":"39","author":"Gonzalez-Galarza","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.clml.2023.03.001_bib0027","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.mayocp.2015.04.025","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"Suppl","key":"10.1016\/j.clml.2023.03.001_bib0028","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/j.clml.2015.02.006","article-title":"Transformative clinical trials in non-hodgkin and hodgkin lymphomas","volume":"15","author":"Abramson","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.03.001_bib0029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11864-016-0401-9","article-title":"Checkpoint Inhibitors and other immune therapies for hodgkin and non-hodgkin lymphoma","volume":"17","author":"Matsuki","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.03.001_bib0031","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.4049\/jimmunol.1502469","article-title":"KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV","volume":"196","author":"Boudreau","year":"2016","journal-title":"J Immunol"},{"issue":"115","key":"10.1016\/j.clml.2023.03.001_bib0032","first-page":"197","article-title":"NK cell-based immunotherapies: awakening the innate anti-cancer response","volume":"21","author":"Souza-Fonseca-Guimaraes","year":"2016","journal-title":"Discov Med"},{"key":"10.1016\/j.clml.2023.03.001_bib0033","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coi.2017.01.003","article-title":"Targeting NK-cell checkpoints for cancer immunotherapy","volume":"45","author":"Muntasell","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"10.1016\/j.clml.2023.03.001_bib0034","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.clml.2023.03.001_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.exphem.2009.12.007","article-title":"B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression","volume":"38","author":"Borgerding","year":"2010","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.03.001_bib0036","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/ng2077","article-title":"Global diversity and evidence for coevolution of KIR and HLA","volume":"39","author":"Single","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2023.03.001_bib0037","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.1097670","article-title":"HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection","volume":"305","author":"Khakoo","year":"2004","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.clml.2023.03.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002565","article-title":"Significant association of KIR2DL3-HLA-C1 combination with cerebral malaria and implications for co-evolution of KIR and HLA","volume":"8","author":"Hirayasu","year":"2012","journal-title":"PLoS Pathog"},{"issue":"10","key":"10.1016\/j.clml.2023.03.001_bib0039","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.humimm.2016.07.003","article-title":"Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in I improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies","volume":"77","author":"Cardozo","year":"2016","journal-title":"Hum Immunol"},{"issue":"4","key":"10.1016\/j.clml.2023.03.001_bib0040","first-page":"794","article-title":"The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation","volume":"48","author":"Hoseinian","year":"2018","journal-title":"Turk J Med Sci"},{"issue":"3","key":"10.1016\/j.clml.2023.03.001_bib0041","doi-asserted-by":"crossref","first-page":"E546","DOI":"10.3390\/ijms20030546","article-title":"Killer Immunoglobulin-Like Receptor 2DS2 (KIR2DS2), KIR2DL2-HLA-C1, and KIR2DL3 as genetic markers for stratifying the risk of cytomegalovirus infection in kidney transplant recipients","volume":"20","author":"Deborska-Materkowska","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clml.2023.03.001_bib0042","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.humimm.2017.07.010","article-title":"Distribution of KIR genes and KIR2DS4 gene variants in two Mexican Mestizo populations","volume":"78","author":"Machado-Sulbaran","year":"2017","journal-title":"Hum Immunol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:20Z","timestamp":1761871280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2152265023000757"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of KIR Genes Polymorphism and its HLA Ligands in Diffuse Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}